Hal­da adds $126M to test oral drugs for prostate, breast can­cer

9 months ago
Financing
Startups

FDA de­lays ap­proval de­ci­sion on Hu­ma­cyte’s lab-grown blood ves­sels

9 months ago
FDA+

Lat­est on MD­MA re­jec­tion; No­vo vs. Lil­ly earn­ings; Re­cur­sion, Ex­sci­en­tia to merge; Q&A with Genen­tech CEO; and more

10 months ago
Weekly

Lykos’ MD­MA-as­sist­ed PTSD treat­ment re­ject­ed by FDA af­ter trou­bled tri­al and push­back from ex­perts

10 months ago
Pharma
FDA+

Ohio fed­er­al judge dis­miss­es IRA suit brought by US Cham­ber of Com­merce

10 months ago
Pharma
Law

Am­gen an­nounces plans for new site in In­dia to strength­en AI, da­ta and life sci­ences

10 months ago
R&D
Pharma

Hel­lo, neffy: FDA ap­proves first nasal spray for se­vere al­ler­gic re­ac­tions

10 months ago
Pharma
FDA+

Genen­tech, Gilead push FDA to mod­ern­ize re­search in­spec­tions

10 months ago
R&D
FDA+

Al­fasig­ma's PBC treat­ment Ocali­va to face an FDA ad­comm in Sep­tem­ber

10 months ago
Pharma
FDA+

23andMe trades drug dis­cov­ery for GLP-1 weight loss pre­scrip­tions

10 months ago
Pharma
Health Tech

Au­toim­mune CAR-Ts are un­der the mi­cro­scope af­ter Ca­balet­ta’s safe­ty is­sue in lu­pus

10 months ago
R&D

Avid­i­ty CEO says it's ‘full steam ahead’ in DMD as stock ral­lies on Phase 1/2 win

10 months ago
R&D

A CAR-T deal in Chi­na; Zevra’s $60M of­fer­ing

10 months ago
News Briefing

No­vavax plots to re­duce Eu­ro­pean foot­print to be­come a ‘lean­er’ com­pa­ny

10 months ago
Pharma
Manufacturing

FDA lifts hold on 4DMT's Fab­ry gene ther­a­py

10 months ago
R&D
Cell/Gene Tx

Mer­ck pays $700M for clin­i­cal-stage CD3xCD19 bis­pe­cif­ic an­ti­body

10 months ago
Deals
China

Ex­clu­sive: MIT spin­out launch­es with fo­cus on im­prov­ing DNA pay­loads for gene in­ser­tion

10 months ago
Financing
Startups

Bill Haney's Drag­on­fly nabs for­mer Cerev­el CFO; Cel­lec­tis' new CMO

10 months ago
People
Peer Review

In­fec­tious dis­ease biotech un­der­goes makeover af­ter lung dis­ease tri­al un­der­whelms

10 months ago
People
R&D

Gilead shells out $320M to J&J to buy out rare liv­er dis­ease drug roy­al­ties

10 months ago
Deals
Pharma

Pur­due’s emer­gency opi­oid over­dose treat­ment is ap­proved by the FDA

10 months ago
Pharma
FDA+

Aldeyra to re­sub­mit dry eye dis­ease drug this year fol­low­ing pos­i­tive Phase 3 da­ta

10 months ago
R&D

Lil­ly says to ‘take some cau­tion’ on oth­er com­pa­nies’ ear­ly-stage obe­si­ty da­ta, calls out com­pounders

10 months ago
Pharma

Lil­ly con­tributes to iso­tope sup­pli­er fundraise; Lay­offs at Aji­nomo­to   

10 months ago
Manufacturing
First page Previous page 118119120121122123124 Next page Last page
A service from the Financial Times